JP2024514101A5 - - Google Patents

Info

Publication number
JP2024514101A5
JP2024514101A5 JP2023560806A JP2023560806A JP2024514101A5 JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5 JP 2023560806 A JP2023560806 A JP 2023560806A JP 2023560806 A JP2023560806 A JP 2023560806A JP 2024514101 A5 JP2024514101 A5 JP 2024514101A5
Authority
JP
Japan
Prior art keywords
domain
chimeric antigen
antigen receptor
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514101A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023112 external-priority patent/WO2022212879A1/en
Publication of JP2024514101A publication Critical patent/JP2024514101A/ja
Publication of JP2024514101A5 publication Critical patent/JP2024514101A5/ja
Pending legal-status Critical Current

Links

JP2023560806A 2021-04-01 2022-04-01 Ｉｌ－１３ｒａ２キメラ抗原受容体および使用方法 Pending JP2024514101A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163169575P 2021-04-01 2021-04-01
US63/169,575 2021-04-01
PCT/US2022/023112 WO2022212879A1 (en) 2021-04-01 2022-04-01 Il-13ra2 chimeric antigen receptors and methods of use

Publications (2)

Publication Number Publication Date
JP2024514101A JP2024514101A (ja) 2024-03-28
JP2024514101A5 true JP2024514101A5 (cg-RX-API-DMAC7.html) 2025-04-08

Family

ID=81384926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560806A Pending JP2024514101A (ja) 2021-04-01 2022-04-01 Ｉｌ－１３ｒａ２キメラ抗原受容体および使用方法

Country Status (4)

Country Link
US (1) US20240189351A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314069A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024514101A (cg-RX-API-DMAC7.html)
WO (1) WO2022212879A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4588939A1 (en) * 2024-01-16 2025-07-23 Universitat de Barcelona Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107683289B (zh) * 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
CN108456250B (zh) * 2017-02-17 2025-11-28 恺兴生命科技(上海)有限公司 靶向il-13ra2的抗体及其应用
CN118374493A (zh) 2017-05-17 2024-07-23 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
EP3765041A4 (en) * 2018-03-14 2021-12-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) IL-13 CHIMERIC RECEPTOR ALPHA 2 (IL13RA2) ANTIGEN RECEPTOR FOR T-CELL T-CELL IMMUNOTHERAPY
WO2020210665A1 (en) * 2019-04-12 2020-10-15 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors with cd20 safety switch

Similar Documents

Publication Publication Date Title
TWI883026B (zh) 抗ｄｌｌ３嵌合抗原受體及其用途
JP2023162180A (ja) ヒト化抗ｍｕｃ１＊抗体
JP2021510710A5 (cg-RX-API-DMAC7.html)
CN112639102A (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
JP2019513370A5 (cg-RX-API-DMAC7.html)
JP2015513920A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2023550998A5 (cg-RX-API-DMAC7.html)
EP3405494A1 (en) Ror2 antibody compositions and related methods
CN108138172B (zh) 抗体
JP7496965B2 (ja) Ｂｃｍａに特異的な抗体およびキメラ抗原受容体
JP2022535410A5 (cg-RX-API-DMAC7.html)
JP2022525318A5 (cg-RX-API-DMAC7.html)
IL316226A (en) Anti-ror1 antibody and ror1-targeting engineered cells
AU2022353119A1 (en) Composition of recombinant antigen binding molecules and method of making and using thereof
JP2024105603A (ja) ＣＡＲライブラリおよびｓｃＦｖの製造方法
JP2024514101A5 (cg-RX-API-DMAC7.html)
Pfeifer Serrahima et al. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies
CA3174678A1 (en) Compositions and methods for treatment of cancer
CN114007626A (zh) 用于治疗癌症的组合物和方法
WO2024037628A1 (zh) 一种双特异性抗体及其应用
JP2024539079A5 (cg-RX-API-DMAC7.html)
JP2023549441A5 (cg-RX-API-DMAC7.html)